Bank of New York Mellon
NAMS icon

Bank of New York Mellon’s NewAmsterdam Pharma NAMS Stock Holding History

Bank of New York Mellon’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12M Sell
353,298
-25,502
-7% -$840K ﹤0.01% 1929
2026
Q1 		$12.1M Sell
378,800
-13,027
-3% -$424K ﹤0.01% 1827
2025
Q4 		$13.7M Buy
391,827
+58,829
+18% +$2.14M ﹤0.01% 1739
2025
Q3 		$9.47M Sell
332,998
-19,954
-6% -$478K ﹤0.01% 1962
2025
Q2 		$6.39M Buy
+352,952
New +$6.44M ﹤0.01% 2134

Other funds holding NAMS

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Bank of New York Mellon's NAMS Position: Q2 2026 in Review

Bank of New York Mellon reduced its NewAmsterdam Pharma (NAMS) stake by 6.7% in Q2 2026, selling an estimated $840K and leaving 353,298 shares worth $12M. The position accounts for ﹤0.01% of the portfolio, ranked #1929.

Bank of New York Mellon first reported a position in NAMS in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.7M in Q4 2025. 78 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • Bank of New York Mellon held 353,298 shares of NewAmsterdam Pharma worth $12M as of Q2 2026.
  • Bank of New York Mellon sold 25,502 NewAmsterdam Pharma shares in Q2 2026, an estimated $840K.
  • NewAmsterdam Pharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1929 holding.
  • Bank of New York Mellon first reported a position in NewAmsterdam Pharma in Q2 2025 and has held it in 5 quarters since.
  • Bank of New York Mellon's NewAmsterdam Pharma position peaked at $13.7M in Q4 2025.
  • 78 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.